PFA
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Shree Ganesh Biotech reported standalone revenue of Rs. 2,295.76 lakhs for FY26, up from Rs. 497.05 lakhs in FY25—a massive 362% increase. However, the company posted a net profit after tax of Rs. 27.84 lakhs, down from Rs. 37.76 lakhs the prior year (26% decline). Total expenses of Rs. 2,401.16 lakhs nearly matched total income of Rs. 2,439.85 lakhs, resulting in tight operating margins. The balance sheet shows Rs. 4,274.88 lakhs in long-term loans against minimal fixed assets of Rs. 0.13 lakhs, suggesting the company operates primarily as a financial services/loan business rather than a typical biotech manufacturer. The statutory auditor issued an Unmodified Opinion confirming clean financials. Cash flow from operating activities was negative at Rs. 819.56 lakhs.
The stock may see mixed reactions—the top-line growth is impressive but shrinking margins and declining PAT suggest underlying profitability issues. The unusual balance sheet composition (heavy loans, minimal assets) warrants caution for investors seeking a genuine biotech play.